Mesa Laboratories, Inc. (NASDAQ:MLAB - Get Free Report) hit a new 52-week high during mid-day trading on Wednesday following a stronger than expected earnings report. The company traded as high as $152.75 and last traded at $137.27, with a volume of 68479 shares. The stock had previously closed at $133.93.
The medical instruments supplier reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.41 by $0.66. Mesa Laboratories had a negative net margin of 104.92% and a positive return on equity of 30.23%.
Mesa Laboratories Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 17th. Stockholders of record on Friday, February 28th will be issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.43%. The ex-dividend date is Friday, February 28th. Mesa Laboratories's payout ratio is currently -1.38%.
Wall Street Analyst Weigh In
Separately, StockNews.com downgraded Mesa Laboratories from a "buy" rating to a "hold" rating in a research report on Wednesday, November 13th.
View Our Latest Research Report on MLAB
Institutional Trading of Mesa Laboratories
A number of institutional investors have recently made changes to their positions in the stock. Sanctuary Advisors LLC purchased a new position in Mesa Laboratories during the 2nd quarter valued at about $183,000. SG Americas Securities LLC purchased a new position in Mesa Laboratories during the 3rd quarter valued at $302,000. Creative Planning lifted its position in shares of Mesa Laboratories by 100.3% in the 3rd quarter. Creative Planning now owns 5,389 shares of the medical instruments supplier's stock worth $700,000 after purchasing an additional 2,698 shares during the period. Berry Wealth Group LP bought a new stake in shares of Mesa Laboratories during the 3rd quarter valued at about $204,000. Finally, Rice Hall James & Associates LLC raised its stake in Mesa Laboratories by 44.1% in the third quarter. Rice Hall James & Associates LLC now owns 22,108 shares of the medical instruments supplier's stock worth $2,871,000 after buying an additional 6,766 shares in the last quarter. Hedge funds and other institutional investors own 90.60% of the company's stock.
Mesa Laboratories Stock Up 4.3 %
The company's fifty day simple moving average is $134.75 and its 200 day simple moving average is $126.03. The company has a quick ratio of 0.51, a current ratio of 0.71 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $802.50 million, a PE ratio of -3.19 and a beta of 0.83.
About Mesa Laboratories
(
Get Free Report)
Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.
Featured Articles
Before you consider Mesa Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesa Laboratories wasn't on the list.
While Mesa Laboratories currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
